(NASDAQ:NYAX),(TASE:NYAX),(TASE:NYAX.TA), HERZLIYA, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) (the “Company”) announced today, further to its announcements of December 7, 2025 and December 8, 2025, that the Company completed an offering in Israel by way of the expansion of its Series A Notes and Series 1 Warrants (the “Notes” […]

(NASDAQ:GRI), Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing approved treatments Study met its secondary endpoints and demonstrated improvement in biomarkers of collagen turnover, suggesting a resolution of fibrosis

(NYSE:TE), AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) — T1 Energy Inc. (NYSE: TE) (“T1,” “T1 Energy,” or the “Company”) today announced proposed underwritten public offerings of $120.0 million aggregate principal amount of its convertible senior notes due 2030 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $140.0 million of its shares

(NYSE:PRM), CLAYTON, Mo., Dec. 10, 2025 (GLOBE NEWSWIRE) — Perimeter Solutions, Inc. (NYSE: PRM) (“Perimeter,” “Perimeter Solutions,” or the “Company”), today announced that it has entered into a definitive agreement to acquire Medical Manufacturing Technologies LLC (“MMT”) from Arcline Investment Management for approximately $685 million in cash, including certain tax benefits. MMT is a leading

(NASDAQ:AARD), Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial SAN DIEGO,

(NasdaqGM:BBOT), Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy and in combination with standard of care therapies in mutant or wild-type PIK3CA breast cancer models BBOT will also present a trial in progress poster on BREAKER-101,

(NASDAQ:HOOD), MENLO PARK, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported select monthly operating data for November 2025. Funded Customers at the end of November were 26.9 million (down approximately 130 thousand from the end of October 2025, up approximately 2.10 million year-over-year). This includes the impact of

(NYSE:DLNG), ATHENS, Greece, Dec. 10, 2025 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (the “Partnership”) (NYSE: DLNG), an owner of liquefied natural gas carriers, announced today that its Board of Directors has authorized a new program under which the Partnership may, from time to time, repurchase up to an aggregate of $10 million of its

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Third Quarter Results GlobeNewswire December 10, 2025 ATLANTA, Dec. 10, 2025 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its third quarter of fiscal 2025 ended November 1, 2025. Consolidated net sales in the third quarter of fiscal 2025 were

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) GlobeNewswire December 10, 2025 Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing approved